These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 31880125)
21. Clinicopathological significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma. Hirokawa T; Arimasu Y; Chiba T; Fujiwara M; Kamma H Pathol Int; 2020 Apr; 70(4):217-223. PubMed ID: 31943527 [TBL] [Abstract][Full Text] [Related]
22. The Genetic Duet of Liu J; Liu R; Shen X; Zhu G; Li B; Xing M J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570 [No Abstract] [Full Text] [Related]
23. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population. Li M; Jia H; Qian Q; Wen P; Chen C; Hua Y; Wang K; Zhang W; Shi F Diagn Pathol; 2020 May; 15(1):49. PubMed ID: 32393293 [TBL] [Abstract][Full Text] [Related]
25. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719 [TBL] [Abstract][Full Text] [Related]
26. Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer. Sang Y; Hu G; Xue J; Chen M; Hong S; Liu R Endocrine; 2024 Jul; 85(1):304-312. PubMed ID: 38356100 [TBL] [Abstract][Full Text] [Related]
27. Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study. Huang J; Wang J; Xv J; Wang J; Wang G; Zhao Y Clin Exp Med; 2024 Apr; 24(1):76. PubMed ID: 38607456 [TBL] [Abstract][Full Text] [Related]
28. TERT promoter mutations in thyroid cancer. Liu R; Xing M Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501 [TBL] [Abstract][Full Text] [Related]
29. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. Lee J; Ha EJ; Roh J; Kim HK Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391 [TBL] [Abstract][Full Text] [Related]
30. A six-genotype genetic prognostic model for papillary thyroid cancer. Shen X; Liu R; Xing M Endocr Relat Cancer; 2017 Jan; 24(1):41-52. PubMed ID: 27875244 [TBL] [Abstract][Full Text] [Related]
31. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252 [TBL] [Abstract][Full Text] [Related]
32. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237 [TBL] [Abstract][Full Text] [Related]
33. Lymph Node Metastasis in Papillary Thyroid Carcinoma, A Study of BRAF V600E and TERT Promoter Mutations. Soeratman AR; Kartini D; Andinata B; Harahap AS; Sudarsono NC Asian Pac J Cancer Prev; 2024 Jun; 25(6):2043-2049. PubMed ID: 38918666 [TBL] [Abstract][Full Text] [Related]
34. Single Point Mutations in Pediatric Differentiated Thyroid Cancer. Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297 [TBL] [Abstract][Full Text] [Related]
35. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077 [TBL] [Abstract][Full Text] [Related]
36. BRAF, TERT and HLA-G Status in the Papillary Thyroid Carcinoma: A Clinicopathological Association Study. Bertol BC; Massaro JD; Debortoli G; Santos ALP; de Araújo JNG; Giorgenon TMV; Costa E Silva M; de Figueiredo-Feitosa NL; Collares CVA; de Freitas LCC; Soares EG; Neder L; Silbiger VN; Calado RT; Maciel LMZ; Donadi EA Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569841 [TBL] [Abstract][Full Text] [Related]
37. Co-existence of Ren H; Shen Y; Hu D; He W; Zhou J; Cao Y; Mao Y; Dou Y; Xiong W; Xiao Q; Zhang Y; Su X Cancer Manag Res; 2018; 10():1005-1013. PubMed ID: 29760568 [TBL] [Abstract][Full Text] [Related]
38. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report. Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206 [TBL] [Abstract][Full Text] [Related]
39. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma. Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401 [TBL] [Abstract][Full Text] [Related]
40. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]